These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Dabrafenib plus trametinib in BRAF K601E-mutant melanoma. Rogiers A; Thomas D; Vander Borght S; van den Oord JJ; Bechter O; Dewaele M; Rambow F; Marine JC; Wolter P Br J Dermatol; 2019 Feb; 180(2):421-422. PubMed ID: 30248172 [No Abstract] [Full Text] [Related]
4. Durable Response to Combination of Dabrafenib and Trametinib in BRAF V600E-Mutated Non-small-cell Lung Cancer. Pervere LM; Rakshit S; Schrock AB; Miller VA; Ali SM; Velcheti V Clin Lung Cancer; 2017 May; 18(3):e211-e213. PubMed ID: 28024926 [No Abstract] [Full Text] [Related]
5. BRAF Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031 [TBL] [Abstract][Full Text] [Related]
6. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. Menzies AM; Long GV Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796 [TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non-Small Cell Lung Cancers Harboring Odogwu L; Mathieu L; Blumenthal G; Larkins E; Goldberg KB; Griffin N; Bijwaard K; Lee EY; Philip R; Jiang X; Rodriguez L; McKee AE; Keegan P; Pazdur R Oncologist; 2018 Jun; 23(6):740-745. PubMed ID: 29438093 [TBL] [Abstract][Full Text] [Related]
8. Dabrafenib plus trametinib in patients with previously untreated BRAF Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011 [TBL] [Abstract][Full Text] [Related]
9. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819 [TBL] [Abstract][Full Text] [Related]
10. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation. Dhillon S Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822 [TBL] [Abstract][Full Text] [Related]
11. Combined BRAF, EGFR, and MEK Inhibition in Patients with Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699 [TBL] [Abstract][Full Text] [Related]
12. A rare BRAF T599dup mutation conferring sensitivity to BRAF inhibitor in a patient with metastatic melanoma. Marchand A; Tallet A; Collin C; Cormier B; Venel Y; Miquelestorena-Standley E; Machet L Br J Dermatol; 2018 Aug; 179(2):528-529. PubMed ID: 29494756 [No Abstract] [Full Text] [Related]
13. Dabrafenib Effective in Pediatric Glioma. Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673 [TBL] [Abstract][Full Text] [Related]
15. Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib. Sasaki K; Nakamura Y; Baba N; Teramoto Y; Yamamoto A Eur J Cancer; 2020 Nov; 139():37-40. PubMed ID: 32957012 [No Abstract] [Full Text] [Related]
16. Dabrafenib and trametinib therapy in an elderly patient with non-small cell lung cancer harboring the BRAF V600E mutation. Dotsu Y; Fukuda M; Honda N; Gyotoku H; Kohno Y; Suyama T; Umeyama Y; Taniguchi H; Takemoto S; Yamaguchi H; Miyazaki T; Sakamoto N; Obase Y; Ikeda H; Ashizawa K; Mukae H Thorac Cancer; 2021 Jan; 12(2):272-276. PubMed ID: 33215864 [TBL] [Abstract][Full Text] [Related]
17. Dabrafenib Active in Rare NSCLC Subtype. Cancer Discov; 2016 Jul; 6(7):OF4. PubMed ID: 27207893 [TBL] [Abstract][Full Text] [Related]
18. Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAF White PS; Pudusseri A; Lee SL; Eton O Thyroid; 2017 Sep; 27(9):1201-1205. PubMed ID: 28805135 [TBL] [Abstract][Full Text] [Related]